Features

What have been the key moves—capacity additions and acquisitions by CDMOs thus far in 2026 and what may be on the horizon?

Excipients play a crucial role in formulation development, but what barriers to innovation in excipients exist and how is the industry addressing?

What have been the key mergers and acquisitions by the large and mid-sized pharma companies thus far in 2026? DCAT Value Chain Insights evaluates the deal-making and the molecules involved. 

AstraZeneca’s strategy to increase its revenues in the US is accompanied by select investments in China on an R&D and manufacturing basis, with the latest, plans for a biomanufacturing JV.

An estimated $500 billion in branded innovator drugs face generics/biosimilar exposure between 2026 and 2032. Which companies and products face the potential greatest impact?

In her first earnings report since becoming CEO of Sanofi in late April, Belén Garijo laid out an accelerated transformation roadmap for the company that focuses on the company’s commercial strengths but also the need for R&D and pipeline improvements.

President Trump announced this week a phased plan to impose tariffs on imported generic drugs into the US as a means to encourage US-based production of generics, and a previously announced executive action for tariffs on patented drugs is coming due. 

Several bio/pharma majors are making a play in in vivo cell therapies with recent $1-billion-plus acquisitions with an aim for both clinical and manufacturing benefits. Are in vivo cell therapies the up-and-coming segment in advanced therapies?

Johnson & Johnson is aiming to cross the $100-billion revenue mark in 2026 and is beginning a multi-year supply-chain restructuring program in its Innovative Medicine segment.

Solid dosage drugs are a steady segment in the global bio/pharma industry, but how do they measure in new drug approvals? A look at the dosage forms of new drug approvals thus far in 2026 and the market potential of some key solid dosage drugs.